Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was founded in 1995 and is headquartered in Madison, Wisconsin.
Industry, Sector and Symbol
Industry Commercial physical research
Sub-IndustryBiotechnology
SectorMedical
Phone608-284-5700
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$265.99 million
Profitability
Miscellaneous
Employees1,268
OptionableOptionable
EXACT Sciences (NASDAQ:EXAS) Frequently Asked Questions
What is EXACT Sciences' stock symbol?
EXACT Sciences trades on the NASDAQ under the ticker symbol "EXAS."
How were EXACT Sciences' earnings last quarter?
EXACT Sciences Co. (NASDAQ:EXAS) released its quarterly earnings data on Tuesday, October, 30th. The medical research company reported ($0.37) earnings per share for the quarter, beating analysts' consensus estimates of ($0.42) by $0.05. The medical research company had revenue of $118.29 million for the quarter, compared to the consensus estimate of $109.33 million. EXACT Sciences had a negative return on equity of 20.18% and a negative net margin of 35.83%. The company's quarterly revenue was up 63.0% on a year-over-year basis. During the same period in the previous year, the business earned ($0.23) earnings per share. View EXACT Sciences' Earnings History.
When is EXACT Sciences' next earnings date?
How can I listen to EXACT Sciences' earnings call?
EXACT Sciences will be holding an earnings conference call on Thursday, February 21st at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 8772010168.
What guidance has EXACT Sciences issued on next quarter's earnings?
EXACT Sciences issued an update on its FY 2018 earnings guidance on Monday, January, 7th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $454-455 million, compared to the consensus revenue estimate of $438.39 million.EXACT Sciences also updated its Q4 2018 guidance to EPS.
What price target have analysts set for EXAS?
12 brokers have issued 1-year price objectives for EXACT Sciences' shares. Their forecasts range from $74.00 to $109.00. On average, they anticipate EXACT Sciences' stock price to reach $89.90 in the next twelve months. This suggests a possible upside of 1.5% from the stock's current price. View Analyst Price Targets for EXACT Sciences.
What is the consensus analysts' recommendation for EXACT Sciences?
12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for EXACT Sciences in the last year. There are currently 2 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for EXACT Sciences.
Has EXACT Sciences been receiving favorable news coverage?
News coverage about EXAS stock has been trending somewhat positive this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. EXACT Sciences earned a news impact score of 1.4 on InfoTrie's scale. They also gave media stories about the medical research company a news buzz of 1.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future.
Who are some of EXACT Sciences' key competitors?
Some companies that are related to EXACT Sciences include Iqvia (IQV), Incyte (INCY), Icon (ICLR), PRA Health Sciences (PRAH), Charles River Laboratories Intl. (CRL), Exelixis (EXEL), Syneos Health (SYNH), BTG (BTGGF), Medpace (MEDP), Intrexon (XON), Eloxx Pharmaceuticals (ELOX), Sorrento Therapeutics (SRNE), STARPHARMA HOLD/S (SPHRY), Pieris Pharmaceuticals (PIRS) and Anavex Life Sciences (AVXL).
Who are EXACT Sciences' key executives?
EXACT Sciences' management team includes the folowing people:
- Mr. Kevin T. Conroy, Chairman, Pres & CEO (Age 53)
- Mr. Jeffrey T. Elliott CFA, CFO & Chief Accounting Officer (Age 41)
- Mr. Graham P. Lidgard, Chief Science Officer (Age 70)
- Mr. D. Scott Coward, Chief Admin. Officer, Sr. VP, Gen. Counsel & Sec. (Age 54)
- Mr. Gary Frings, Chief Information Officer
Who are EXACT Sciences' major shareholders?
EXACT Sciences' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Frontier Capital Management Co. LLC (1.00%), Geode Capital Management LLC (0.97%), Jennison Associates LLC (0.85%), Eagle Asset Management Inc. (0.81%), CIBC Private Wealth Group LLC (0.74%) and Baillie Gifford & Co. (0.72%). Company insiders that own EXACT Sciences stock include D Scott Coward, Graham Peter Lidgard, Jeffrey Thomas Elliott, Katherine S Zanotti, Kevin T Conroy, Maneesh Arora, Michael S Wyzga and Thomas D Carey. View Institutional Ownership Trends for EXACT Sciences.
Which institutional investors are selling EXACT Sciences stock?
EXAS stock was sold by a variety of institutional investors in the last quarter, including GABELLI & Co INVESTMENT ADVISERS INC., Frontier Capital Management Co. LLC, KAMES CAPITAL plc, Eagle Asset Management Inc., Victory Capital Management Inc., CIBC Private Wealth Group LLC, Macquarie Group Ltd. and Kornitzer Capital Management Inc. KS. Company insiders that have sold EXACT Sciences company stock in the last year include D Scott Coward, Graham Peter Lidgard, Jeffrey Thomas Elliott, Katherine S Zanotti, Kevin T Conroy, Maneesh Arora, Michael S Wyzga and Thomas D Carey. View Insider Buying and Selling for EXACT Sciences.
Which institutional investors are buying EXACT Sciences stock?
EXAS stock was bought by a variety of institutional investors in the last quarter, including Eaton Vance Management, First Trust Advisors LP, Intrinsic Edge Capital Management LLC, Geode Capital Management LLC, R.H. Dinel Investment Counsel Inc., Foresters Investment Management Company Inc., Columbus Circle Investors and Wisconsin Capital Management LLC. View Insider Buying and Selling for EXACT Sciences.
How do I buy shares of EXACT Sciences?
Shares of EXAS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is EXACT Sciences' stock price today?
One share of EXAS stock can currently be purchased for approximately $88.55.
How big of a company is EXACT Sciences?
EXACT Sciences has a market capitalization of $10.88 billion and generates $265.99 million in revenue each year. The medical research company earns $-114,390,000.00 in net income (profit) each year or ($0.99) on an earnings per share basis. EXACT Sciences employs 1,268 workers across the globe.
What is EXACT Sciences' official website?
How can I contact EXACT Sciences?
EXACT Sciences' mailing address is 441 CHARMANY DRIVE, MADISON WI, 53719. The medical research company can be reached via phone at 608-284-5700.
MarketBeat Community Rating for EXACT Sciences (NASDAQ EXAS)
MarketBeat's community ratings are surveys of what our community members think about EXACT Sciences and other stocks. Vote "Outperform" if you believe EXAS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EXAS will underperform the S&P 500 over the long term. You may vote once every thirty days.
